<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(5)</volume><submitter>Kalhotra P</submitter><pubmed_abstract>Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the treatment for diabetic patients. Recently, natural compounds have been proven to inhibit DPP-4 with fewer side effects. In this work, initially, molecular docking simulations revealed that a natural compound, Galangin, possess a binding energy of -24 KJ/mol and interaction residues SER 630 and TYR 547, that are responsible for potent DPP-4 inhibition. In vitro studies showed that galangin not only inhibits DPP-4 in a concentration-dependent manner but also regulates glucose levels, enabling the prol</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>E1228</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6429117</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.</pubmed_title><pmcid>PMC6429117</pmcid><pubmed_authors>Gallardo-Velazquez T</pubmed_authors><pubmed_authors>Chittepu VCSR</pubmed_authors><pubmed_authors>Osorio-Revilla G</pubmed_authors><pubmed_authors>Kalhotra P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.</name><description>Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the treatment for diabetic patients. Recently, natural compounds have been proven to inhibit DPP-4 with fewer side effects. In this work, initially, molecular docking simulations revealed that a natural compound, Galangin, possess a binding energy of -24 KJ/mol and interaction residues SER 630 and TYR 547, that are responsible for potent DPP-4 inhibition. In vitro studies showed that galangin not only inhibits DPP-4 in a concentration-dependent manner but also regulates glucose levels, enabling the prol</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Mar</publication><modification>2026-04-30T23:55:33.574Z</modification><creation>2025-05-29T22:08:06.681Z</creation></dates><accession>S-EPMC6429117</accession><cross_references><pubmed>30862104</pubmed><doi>10.3390/ijms20051228</doi></cross_references></HashMap>